WO2006023576A3 - Etablissement de profils pharmacologiques de medicaments avec des dosages a base de cellules - Google Patents

Etablissement de profils pharmacologiques de medicaments avec des dosages a base de cellules Download PDF

Info

Publication number
WO2006023576A3
WO2006023576A3 PCT/US2005/029278 US2005029278W WO2006023576A3 WO 2006023576 A3 WO2006023576 A3 WO 2006023576A3 US 2005029278 W US2005029278 W US 2005029278W WO 2006023576 A3 WO2006023576 A3 WO 2006023576A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
drugs
amount
protein
profile
cell
Prior art date
Application number
PCT/US2005/029278
Other languages
English (en)
Other versions
WO2006023576A2 (fr )
Inventor
Marnie L Macdonald
John K Westwick
Helen Yu
Original Assignee
Odyssey Thera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5097Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving plant cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/10Post-translational modifications [PTMs] in chemical analysis of biological material acylation, e.g. acetylation, formylation, lipoylation, myristoylation, palmitoylation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/12Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/36Post-translational modifications [PTMs] in chemical analysis of biological material addition of addition of other proteins or peptides, e.g. SUMOylation, ubiquitination
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Abstract

La présente invention concerne une technique permettant d'établir des profils d'innocuité de composés chimiques ainsi que d'établir des profils pharmacologiques. Cette technique consiste (A) à tester les effets de ces composés chimiques sur la quantité et/ou des modifications post-translationnelles d'au moins deux macromolécules dans des cellules intactes, (B) à construire un profil pharmacologique fondé sur les résultats de ces tests et, (C) à comparer ce profil au(x) profil(s) des médicaments dont les caractéristiques d'innocuité sont établies. Par ailleurs, cette invention concerne aussi une composition comprenant un panneau de dosage, ce panneau comprenant au moins un dosage de grande densité de la quantité et/ou de la modification post-translationnelle d'une protéine et au moins un dosage de grande densité de la quantité et/ou de la localisation subcellulaire d'une interaction protéine-protéine.
PCT/US2005/029278 2004-08-18 2005-08-18 Etablissement de profils pharmacologiques de medicaments avec des dosages a base de cellules WO2006023576A3 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US60231704 true 2004-08-18 2004-08-18
US60/602,317 2004-08-18
US11205021 US20060040338A1 (en) 2004-08-18 2005-08-17 Pharmacological profiling of drugs with cell-based assays

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20050788134 EP1784642A4 (fr) 2004-08-18 2005-08-18 Etablissement de profils pharmacologiques de medicaments avec des dosages a base de cellules
CA 2577152 CA2577152A1 (fr) 2004-08-18 2005-08-18 Etablissement de profils pharmacologiques de medicaments avec des dosages a base de cellules
JP2007527980A JP2008510963A (ja) 2004-08-18 2005-08-18 細胞ベースアッセイを用いた薬物の薬理学的プロファイリング

Publications (2)

Publication Number Publication Date
WO2006023576A2 true WO2006023576A2 (fr) 2006-03-02
WO2006023576A3 true true WO2006023576A3 (fr) 2006-07-06

Family

ID=35910070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/029278 WO2006023576A3 (fr) 2004-08-18 2005-08-18 Etablissement de profils pharmacologiques de medicaments avec des dosages a base de cellules

Country Status (5)

Country Link
US (1) US20060040338A1 (fr)
EP (3) EP2341345A1 (fr)
JP (2) JP2008510963A (fr)
CA (1) CA2577152A1 (fr)
WO (1) WO2006023576A3 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114615B2 (en) 2006-05-17 2012-02-14 Cernostics, Inc. Method for automated tissue analysis

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563584B2 (en) * 2001-07-10 2009-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of multiple proteins in single cells
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US7381535B2 (en) * 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US7393656B2 (en) * 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US20060094068A1 (en) * 2002-06-19 2006-05-04 Bacus Sarah S Predictive markers in cancer therapy
US20060160109A1 (en) * 2004-11-22 2006-07-20 Odyssey Thera, Inc. Harnessing network biology to improve drug discovery
EP1842147A2 (fr) * 2005-01-24 2007-10-10 The Board of Trustees of The Leland Stanford Junior University Utilisation de reseaux de bayes afin de modeliser des systemes de signalisation des cellules
US9862770B2 (en) * 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
JP2010500577A (ja) * 2006-08-07 2010-01-07 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 癌の予後および予測シグナチャーのプロテオミクスパターン
WO2009134944A3 (fr) * 2008-04-29 2010-02-25 Nodality, Inc. Procédés de détermination de l'état de santé d'un individu
US20090291458A1 (en) * 2008-05-22 2009-11-26 Nodality, Inc. Method for Determining the Status of an Individual
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8227202B2 (en) * 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2010045651A1 (fr) * 2008-10-17 2010-04-22 Nodality, Inc. Procédés d’analyse de réponse à un médicament
US10018631B2 (en) 2011-03-17 2018-07-10 Cernostics, Inc. Systems and compositions for diagnosing Barrett's esophagus and methods of using the same
US8937213B2 (en) 2011-05-21 2015-01-20 Christopher E. Hopkins Transgenic biosensors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103479A (en) * 1996-05-30 2000-08-15 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
US20030166555A1 (en) * 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
DK0983498T3 (da) * 1997-02-27 2004-08-16 Cellomics Inc System for cellebaseret screening
US7062219B2 (en) * 1997-01-31 2006-06-13 Odyssey Thera Inc. Protein fragment complementation assays for high-throughput and high-content screening
US6294330B1 (en) 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
CA2196496A1 (fr) 1997-01-31 1998-07-31 Stephen William Watson Michnick Epreuve de complementation de fragments de proteines pour la detection d'interactions entre proteines
US6828099B2 (en) 1998-02-02 2004-12-07 Odyssey Thera Inc. Protein fragment complementation assay (PCA) for the detection of protein-protein, protein-small molecule and protein nucleic acid interactions based on the E. coli TEM-1 β-Lactamase
US6416959B1 (en) * 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
US6410245B1 (en) * 1998-04-01 2002-06-25 Affymax, Inc. Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions
WO2000007017A3 (fr) * 1998-07-27 2000-05-04 Harvard College Procede d'examen haute efficacite de molecules et de composes en rapport avec leurs effets sur des processus biologiques et chimiques
US6801859B1 (en) 1998-12-23 2004-10-05 Rosetta Inpharmatics Llc Methods of characterizing drug activities using consensus profiles
WO2000068661A9 (fr) * 1999-05-12 2002-07-11 Adrienne S Gordon Detection de l'exposition cellulaire aux drogues engendrant la dependance
US6673554B1 (en) 1999-06-14 2004-01-06 Trellie Bioinformatics, Inc. Protein localization assays for toxicity and antidotes thereto
US6372431B1 (en) 1999-11-19 2002-04-16 Incyte Genomics, Inc. Mammalian toxicological response markers
WO2001074298A3 (fr) * 2000-03-31 2003-05-22 Cristina M Alberini Procedes et compositions pour reguler la consolidation de la memoire
US20040038227A1 (en) * 2000-05-08 2004-02-26 Philippe Verwaerde Method and technology for high-throughput lead profiling
JP2004503256A (ja) * 2000-06-14 2004-02-05 ビスタジェン インコーポレイテッド 肝臓幹細胞を使用する毒性分類
US20020019010A1 (en) * 2000-07-07 2002-02-14 Stockwell Brent R. Methods for identifying combinations of entities as therapeutics
US6794137B2 (en) * 2000-09-08 2004-09-21 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
US20020064769A1 (en) 2000-10-05 2002-05-30 Watson Michnick Stephen William Dynamic visualization of expressed gene networks in living cells
EP1385531B1 (fr) * 2001-02-27 2008-05-07 Blanchette Rockefeller Neurosciences Institute Diagnostic de la maladie d'alzheimer base sur la phosphorylation d'une proteine kinase activee par mitogene
US7085765B2 (en) * 2001-03-12 2006-08-01 Cellomics, Inc. Methods to increase the capacity of high content cell-based screening assays
US20030138819A1 (en) * 2001-10-26 2003-07-24 Haiqing Gong Method for detecting disease
JP2005527210A (ja) * 2002-04-19 2005-09-15 バイオイメージ・アクティーゼルスカブ 薬物スクリーニングのためのトランスロケーション依存的な相補性
CA2484274A1 (fr) * 2002-05-09 2003-12-04 Curagen Corporation Compositions et procedes d'utilisation d'un facteur de croissance de fibroblastes
ES2271634T3 (es) * 2002-06-03 2007-04-16 Pamgene B.V. Metodo para ensayos basados en celulas de alto rendimiento que usan micromatrices vivas versatiles.
CA2496897C (fr) * 2002-08-30 2012-01-31 President And Fellows Of Harvard College Procedes et compositions permettant la modulation de l'activite xbp-1
US20040241636A1 (en) * 2003-05-30 2004-12-02 Michnick Stephen William Watson Monitoring gene silencing and annotating gene function in living cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103479A (en) * 1996-05-30 2000-08-15 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
US20030166555A1 (en) * 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1784642A2 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114615B2 (en) 2006-05-17 2012-02-14 Cernostics, Inc. Method for automated tissue analysis
US8597899B2 (en) 2006-05-17 2013-12-03 Cernostics, Inc. Method for automated tissue analysis

Also Published As

Publication number Publication date Type
JP2014016337A (ja) 2014-01-30 application
JP2008510963A (ja) 2008-04-10 application
EP1784642A4 (fr) 2008-10-22 application
EP2363496A1 (fr) 2011-09-07 application
EP2341345A1 (fr) 2011-07-06 application
CA2577152A1 (fr) 2006-03-02 application
WO2006023576A2 (fr) 2006-03-02 application
US20060040338A1 (en) 2006-02-23 application
EP1784642A2 (fr) 2007-05-16 application

Similar Documents

Publication Publication Date Title
Avery Quantitative characterization of differential ion suppression on liquid chromatography/atmospheric pressure ionization mass spectrometric bioanalytical methods
Pratt et al. Dynamics of protein turnover, a missing dimension in proteomics
Wilm Quantitative proteomics in biological research
Coe et al. Supercritical fluid chromatography–tandem mass spectrometry for fast bioanalysis of R/S-warfarin in human plasma
Rusconi et al. Quantification of sodium dodecyl sulfate in microliter-volume biochemical samples by visible light spectroscopy
Hinsby et al. A wiring of the human nucleolus
Bakhtiar et al. High‐throughput chiral liquid chromatography/tandem mass spectrometry
Liu et al. Recent advances in affinity capillary electrophoresis (2007)
Moon et al. Nanoflow LC/ion mobility/CID/TOF for proteomics: analysis of a human urinary proteome
Kolker et al. Protein identification and expression analysis using mass spectrometry
Remily‐Wood et al. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer
Gennaro et al. Reversed‐phase ion‐pairing liquid chromatography/ion trap mass spectrometry for the analysis of negatively charged, derivatized glycans
Zhang et al. Quantitation of human glutathione S‐transferases in complex matrices by liquid chromatography/tandem mass spectrometry with signature peptides
Gallien et al. Highly multiplexed targeted proteomics using precise control of peptide retention time
Thormann et al. Capillary electrophoresis in clinical toxicology
Tagliaro et al. Recent advances in the application of CE to forensic sciences: a update over years 2007–2009
Yan et al. Europium‐Labeled Activity‐Based Probe through Click Chemistry: Absolute Serine Protease Quantification Using 153Eu Isotope Dilution ICP/MS
Schmitz et al. Capillary electrophoresis analysis of DNA adducts as biomarkers for carcinogenesis
Shinde et al. Imprinted polymers displaying high affinity for sulfated protein fragments
WO2002082083A1 (fr) Electrophorese
WO2007079250A3 (fr) Dispositifs et procedes d'enrichissement et de modification de cellules tumorales circulantes et d'autres particules
Hauser et al. Online microwave D-cleavage LC-ESI-MS/MS of intact proteins: site-specific cleavages at aspartic acid residues and disulfide bonds
Haji-Sulaiman et al. Equilibrium concentration profiles of species in CO2—alkanolamine—water systems
Barrowcliffe et al. The anticoagulant activity of heparin: measurement and relationship to chemical structure
Bache et al. Gas-phase fragmentation of peptides by MALDI in-source decay with limited amide hydrogen (1H/2H) scrambling

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005788134

Country of ref document: EP

Ref document number: 2577152

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005277446

Country of ref document: AU

Ref document number: 2007527980

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005277446

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2005277446

Country of ref document: AU

Date of ref document: 20050818

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005788134

Country of ref document: EP